Rankings
▼
Calendar
▼
CGON Q2 2023 Earnings Report — CG Oncology, Inc. Common stock Revenue & Financial Results | Market Cap Arena
CG Oncology, Inc. Common stock
CGON
Q2 2023 Earnings
Reported June 28, 2023
Quarter Comparison
Revenue
Operating Income
EPS (Diluted)
Free Cash Flow
Metric
Q2 2023
Q1 2023
Q2 2022
QoQ Change
YoY Change
Revenue
$0
$194.0K
—
-100.0%
—
Op. Income
-$12M
-$10M
—
-26.8%
—
EPS (Diluted)
$-0.17
$-0.13
—
-30.8%
—
Free Cash Flow
-$11M
-$8M
—
-35.1%
—
marketcaparena.com
Income Statement
Item
Amount
REVENUE
$0
Cost of Revenue
$4.0K
GROSS PROFIT
-$4.0K
R&D Expenses
$10M
Selling & Marketing
-$4.0K
General & Administrative
$2M
SG&A Expenses
$2M
Other Expenses
-$58.0K
Operating Expenses
$12M
Cost & Expenses
$12M
OPERATING INCOME
-$12M
Interest Income
$771.0K
Interest Expense
$0
Other Income/Expenses
$713.0K
INCOME BEFORE TAX
-$12M
Income Tax Expense
$0
Net Income from Continuing Ops
-$12M
Net Income from Discontinued Ops
$0
Other Adjustments
$0
NET INCOME
-$12M
Net Income Deductions
$0
BOTTOM LINE NET INCOME
-$15M
D&A
$4.0K
EBIT
-$12M
EBITDA
-$12M
EPS
-$0
EPS Diluted
-$0
marketcaparena.com
Cash Flow Statement
Item
Amount
Net Income
-$12M
Depreciation & Amortization
$4.0K
Stock-Based Compensation
$177.0K
Deferred Income Tax
$0
Other Non-Cash Items
$364.0K
Change in Working Capital
$286.0K
OPERATING CASH FLOW
-$11M
Capital Expenditure
$0
Acquisitions (Net)
$0
Purchases of Investments
-$32M
Sales/Maturities of Investments
$136M
Other Investing Activities
$0
NET CASH FROM INVESTING
$103M
Net Debt Issuance
-$15M
Common Stock Repurchased
$0
Common Dividends Paid
$0
Other Financing Activities
$165.0K
NET CASH FROM FINANCING
-$15M
FREE CASH FLOW
-$11M
Net Change in Cash
$77M
marketcaparena.com
← FY 2023
CGON Overview
Q3 2023 →